|
|
|
|
pmid:
|
Finch JL et al. |
Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. |
1999 |
J. Am. Soc. Nephrol. |
pmid:10232683
|
Goldenberg MM |
Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. |
1999 |
Clin Ther |
pmid:10321413
|
Zager RA |
Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack. |
1999 |
Am. J. Pathol. |
pmid:10362817
|
Stephens D et al. |
A statistical experimental approach to cosolvent formulation of a water-insoluble drug. |
1999 |
Drug Dev Ind Pharm |
pmid:10434141
|
Chen TC et al. |
The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. |
2000 |
Clin. Cancer Res. |
pmid:10741714
|
Balint E et al. |
Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. |
2000 |
Am. J. Kidney Dis. |
pmid:11007682
|
Brown AJ et al. |
Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. |
2000 |
J. Am. Soc. Nephrol. |
pmid:11053485
|
Shankar VN et al. |
In vitro metabolism of 19-nor-1alpha, 25-(OH)2D2 in cultured cell lines: inducible synthesis of lipid- and water-soluble metabolites. |
2001 |
Arch. Biochem. Biophys. |
pmid:11370854
|
Finch JL et al. |
Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells. |
2001 |
J. Am. Soc. Nephrol. |
pmid:11423575
|